Skip to main content
Menu
US

AlphaLISA SureFire Ultra Human & Mouse Phospho-SQSTM1 p62 (Ser351) Detection Kit, 100 Assay Points

The AlphaLISA™ SureFire® Ultra™ Human and Mouse Phospho-SQSTM1 p62 (Ser351) assay is a sandwich immunoassay for quantitative detection of phospho-SQSTM1 p62 (Ser351) in cellular lysates using Alpha Technology.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Feature Specification
Application Cell Signaling
Sample Volume 30 µL

The AlphaLISA™ SureFire® Ultra™ Human and Mouse Phospho-SQSTM1 p62 (Ser351) assay is a sandwich immunoassay for quantitative detection of phospho-SQSTM1 p62 (Ser351) in cellular lysates using Alpha Technology.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Product Variants
Unit Size: 100 Assay Points
Part #:
ALSU-PSQSTM-A-HV
List Price
USD 740.59
Unit Size: 10,000 Assay Points
Part #:
ALSU-PSQSTM-A10K
List Price
USD 15,110.00
Unit Size: 50,000 Assay Points
Part #:
ALSU-PSQSTM-A50K
List Price
USD 48,780.00
Unit Size: 500 Assay Points
Part #:
ALSU-PSQSTM-A500
List Price
USD 2,486.00

Overview

Sequestome-1 or ubiquitin binding protein p62 (SQSTM1 p62) is an autophagosome cargo protein that targets other proteins that bind to it for selective autophagy. SQSTM1 p62 is an adaptor protein that has an increased affinity for ubiquitin chains after phosphorylation, thus enabling SQSTM1 p62 to bind to ubiquitinated cargo proteins. Ubiquitinated proteins or ubiquitin-coated mitochondria associated with SQSTM1 p62 proteins are taken away in phagosomes, whose content is cleared out after lysosomal fusion. SQSTM1 p62 is implicated in Alzheimer’s disease, Huntington’s disease, NASH, and numerous types of cancer.

The AlphaLISA SureFire Ultra Human and Mouse Phospho-SQSTM1 p62 (Ser351) is a sandwich immunoassay for the quantitative detection of phospho-SQSTM1 p62 (Ser351) in cellular lysates, using Alpha Technology.

Formats:
  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.
AlphaLISA SureFire Ultra kits are compatible with:
  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies
Alpha SureFire kits can be used for:
  • Cellular kinase assays
  • Receptor activation studies
  • Screening

Specifications

Application
Cell Signaling
Automation Compatible
Yes
Brand
AlphaLISA SureFire Ultra
Detection Modality
Alpha
Lysis Buffer Compatibility
Lysis Buffer
Molecular Modification
Phosphorylation
Product Group
Kit
Sample Volume
30 µL
Shipping Conditions
Shipped in Blue Ice
Target
SQSTM1 p62
Target Class
Phosphoproteins
Target Species
Human
Mouse
Technology
Alpha
Therapeutic Area
Neuroscience
Oncology
Unit Size
100 Assay Points

Image gallery

Video gallery

Resources

Are you looking for resources, click on the resource type to explore further.

1-2 of 2 Resources
Application Note Icon
Application Note
Characterizing Chemokine Receptor Inhibitors with AlphaLISA SureFire Ultra

Therapeutic antibodies directed to cell surface receptors are increasingly being developed as treatments for a variety of diseases...

Application Note Icon
Application Note
Characterizing chemokine receptor inhibitors with AlphaLISA SureFire Ultra, Alpha SureFire Ultra Multiplex and LANCE Ultra cAMP assays

The measurement of protein phosphorylation is a useful tool for measuring the modulation of receptor activation by both antibodies...

Scroll Icon